The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
- 31 August 2011
- journal article
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 43 (2), 364-371
- https://doi.org/10.1016/j.nbd.2011.04.007
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- The Origins of Oxidant Stress in Parkinson's Disease and Therapeutic StrategiesAntioxidants and Redox Signaling, 2011
- Neuronal Calcium Homeostasis and DysregulationAntioxidants and Redox Signaling, 2011
- L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's diseaseNeurobiology of Disease, 2011
- Calcium channel blocker use and risk of Parkinson's diseaseMovement Disorders, 2010
- Pacemaking in Dopaminergic Ventral Tegmental Area Neurons: Depolarizing Drive from Background and Voltage-Dependent Sodium ConductancesJournal of Neuroscience, 2010
- L‐type calcium channel blockers and Parkinson disease in DenmarkAnnals of Neurology, 2010
- IsradipineDrugs, 1990
- Multiple Types of Calcium Channels in Heart Muscle and NeuronsAnnals of the New York Academy of Sciences, 1989
- The Pharmacokinetics of Oral Isradipine in Normal VolunteersThe Journal of Clinical Pharmacology, 1988
- Time course of nigrostriatal degeneration in parkinson's diseaseJournal of Neural Transmission, 1976